Pfizer has revealed that it plans to launch its Nyvepria (pegfilgrastim) biosimilar rival to Amgen’s Neulasta in Europe early next year. The confirmation of the launch plans follows the recent formal European Commission approval of Nyvepria in the wake of a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September. (Also see "Pfizer Picks Up EU Pegfilgrastim Approval" - Generics Bulletin, 24 November, 2020.)
“Pfizer intends to make Nyvepria available to patients in several European countries starting in Q1 2021,” a Pfizer spokesperson told...




